Sernova Corp
TSX VENTURE : SVA

Sernova Corp

January 12, 2015 06:00 ET

Sernova to Participate in Biotech Showcase™ 2015 Healthcare Conference in San Francisco

LONDON, ONTARIO--(Marketwired - Jan. 12, 2015) - Sernova Corp (TSX VENTURE:SVA), announced today that Dr. Philip Toleikis, Ph.D., president and CEO will be participating in the Biotech Showcase™ healthcare conference being held in San Francisco, CA January 12-14, 2015.

"This event provides Sernova in a full roster of business development meetings access to key life science industry investors and biopharmaceutical executives to update them on the Company's business strategy, corporate developments and upcoming goals. This annual gathering is an important and timely event for the Company with over 1,500 executive-level delegates representing qualified private and public equity investors, industry analysts, bankers, pharmaceutical and biotechnology industry executives in attendance willing to listen, invest and explore collaborations and partnerships with an eye to consolidate assets for global market opportunities," remarked Dr. Philip Toleikis, President and CEO.

About the Biotech Showcase™

Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech Showcase, now in its seventh year, is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences.

About Sernova

Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch™, an implantable medical device and locally immune-protected therapeutic cells which then release required proteins and/or hormones in the treatment of disease.

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information